Cargando…
Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial
Pulmonary arterial hypertension (PAH) remains life-limiting despite numerous approved vasodilator therapies. Right ventricular (RV) function determines outcome in PAH but no treatments directly target RV adaptation. PAH is more common in women, yet women have better RV function and survival as compa...
Autores principales: | Walsh, Thomas P., Baird, Grayson L., Atalay, Michael K., Agarwal, Saurabh, Arcuri, Daniel, Klinger, James R., Mullin, Christopher J., Morreo, Heather, Normandin, Brynn, Shiva, Sruti, Whittenhall, Mary, Ventetuolo, Corey E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142004/ https://www.ncbi.nlm.nih.gov/pubmed/34094503 http://dx.doi.org/10.1177/2045894021989554 |
Ejemplares similares
-
The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension
por: Banerjee, Debasree, et al.
Publicado: (2017) -
Reply to Helgeson et al.: Remote 6-minute-Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed?
por: LaPatra, Tess, et al.
Publicado: (2022) -
Sexual health and health-related quality of life among women with
pulmonary arterial hypertension
por: Banerjee, Debasree, et al.
Publicado: (2018) -
Prime Time for Proteomics in Pulmonary Arterial Hypertension Risk Assessment?
por: Singh, Navneet, et al.
Publicado: (2022) -
Another Piece in the Estrogen Puzzle of Pulmonary
Hypertension
por: Al-Naamani, Nadine, et al.
Publicado: (2020)